Benralizumab Hits Mark in Head-to-Head EGPA Vasculitis Trial Benralizumab Hits Mark in Head-to-Head EGPA Vasculitis Trial

In the study, adults with EGPA were randomized to a single 30-mg subcutaneous injection of benralizumab or three separate 100-mg subcutaneous injections of mepolizumab once every 4 weeks.MDedge News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Rheumatology News Source Type: news